Median progression free survival was 16.2 months with olaparib maintenance therapy in L-MOCA. Research teams now have outcome data for 224 treated participants in the single-arm study.
Mean BMI change at week 56 was -6.7% with liraglutide and 2.1% with placebo. Research teams now have main-phase outcome and safety data from a trial of 82 children aged 6 to below 12 years.
Industry sponsors registered 2 Phase 3 trials on ClinicalTrials.gov so far in the week of November 16 to 22, 2026. They plan to enroll 10,120 participants in all; the largest, Novartis Pharmaceuticals' PINNACLE-MI trial, plans to enroll 10,000.
Industry sponsors posted results for 3 Phase 3 trials on ClinicalTrials.gov so far in the week of November 16 to 22, 2026. Together the trials enrolled 345 participants; the largest, AstraZeneca's L-MOCA trial, enrolled 225.
A Priority Review analysis of 18,422 terminated trials on ClinicalTrials.gov. Among industry trials that gave a stop reason, 63.5% of those ended in 2025 cited a sponsor or business decision (407 of 641), up from 31.5% in 2016 (107 of 340). Enrollment fell from 31.8% to 12.3% on the same basis.
The FDA's new draft guidance says early-phase solid tumor trials should in general set no upper age limit, and most already set none. A Priority Review analysis of 11,830 recruiting US trials finds the limits elsewhere: 41.8% of mental health trials and 38.3% of metabolic trials exclude people 80 and older.
A November 2026 FDA draft guidance for sponsors and clinical investigators recommends eligibility, dose escalation, consent and sampling practices for first-in-human and other early-phase solid tumor trials. Comments are due January 11, 2027.
The FDA approved durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer in adults who are ineligible for or refused cisplatin-based chemotherapy. In VOLGA, the hazard ratio for event-free survival was 0.51 against radical cystectomy alone.
The FDA approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy, with complete remission of proteinuria at week 104 in 36% versus 6% on tacrolimus in MAJESTY. The FDA said it is the first drug approved specifically for these adults.
Treatment-emergent adverse events were reported for 104 of 119 adults with idiopathic hypersomnia receiving pitolisant. Long-term safety data and sleepiness scores are now available for participants from a randomized withdrawal study.
The FDA approved pimicotinib (Pimjetmi) on November 10, 2026, after an overall response rate of 56% versus 3.2% on placebo at Week 25. For adults with symptomatic TGCT, an approved kinase inhibitor now exists.
Orphalan said three Chinese hospitals are now recruiting for its 38-participant TRADITiONAL Phase 3 study of once-daily trientine tetrahydrochloride. Wilson disease patients aged 8 years and older can now enroll in the United States and China.
In a Phase 3 sub-study in China, median overall survival was 7.7 months with epcoritamab and 9.0 months with investigator's choice chemotherapy in relapsed or refractory DLBCL. Genmab has now posted randomized results for 72 participants.
Eli Lilly and Company said 43.7 percent of adults with psoriatic arthritis and obesity or overweight reached ACR50 at 52 weeks on Taltz and Zepbound together, against 15.7 percent on Taltz alone. The company gave the figures at ACR Convergence 2026 for the TOGETHER-PsA trial.
CMS estimates Original Medicare improper payment rate at 7.32%, or $33.96 billion, down from 6.55%, or $28.83 billion in FY 2025. Medicare Part C, Part D, Medicaid, CHIP and APTC rates also decline, with most improper payments due to insufficient documentation.
On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.
AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.
The study enrolled 120 participants and was first posted on ClinicalTrials.gov on November 16, 2026. It compared DLBS3233 at 100 mg and 200 mg once daily to Metformin XR 500 mg twice daily over a 12-week course of therapy.
The study, PINNACLE-MI, plans to enroll 10,000 participants and aims to demonstrate superiority of Pacibekitug over placebo in reducing 3-point coronary major adverse cardiovascular events in participants after a Myocardial Infarction. It is scheduled to start on November 30, 2026, with primary completion expected on October 22, 2030.
The company posted first results for its Phase 3 L-MOCA study, enrolling 225 participants who received olaparib 300mg tablets as maintenance therapy after platinum-based chemotherapy. The trial, which began on May 29, 2018, completed primary data collection on January 27, 2025.
The study, completed with 38 participants, compared dasiglucagon and glucagon for treating severe hypoglycaemia in Asian adults with type 1 diabetes. Results were first posted on ClinicalTrials.gov on November 16, 2026.
Results for the 56-week, double-blind, randomized, placebo-controlled trial were first posted on ClinicalTrials.gov on November 16, 2026. The study enrolled 82 children aged 6 to below 12 years to evaluate the effect and safety of liraglutide 3.0 mg on weight management.
The assay, a sandwich immunoassay, quantifies the intact 77-amino-acid Endotrophin hormone at Nordic Bioscience's CLIA lab. It has been measured in more than 50,000 patients with cardio-kidney-metabolic disease.
In a phase 3 trial of 567 participants, once-weekly ribupatide produced least-squares mean weight reductions of -10.7%, -16.4%, and -17.7% at 48 weeks for 2, 4, and 6 mg doses versus -1.4% with placebo. Gastrointestinal events were the most frequent adverse events, occurring in 47.9%, 58.2%, and 63.1% of participants at the three doses.